Helius Med Technolog (HSDT) 2.6000 $HSDT
Helius Medical Technologies Grants Stock Options
ACCESSWIRE - Mon Mar 16, 4:49PM CDT
NEWTOWN, PA / ACCESSWIRE / March 16, 2015 / Helius Medical Technologies, Inc. (CSE: HSM; OTCQB: HSDT) ( "Helius" or "the Company"
, a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, announces that it has granted incentive stock options, exercisable to purchase up to an aggregate of 100,000 shares of the Company, to a director of Helius.
Helius Medical Technologies Announces First Three Subjects Enrolled in Canadian Multiple Sclerosis Feasibility Study
Business Wire - Thu Feb 19, 9:15AM CST
Helius Medical Technologies ("Helius", or the "Company" announced the enrollment of the first three subjects in the Multiple Sclerosis ("MS" feasibility study at the Montreal Neurological Institute and Hospital and Concordia's PERFORM Center. The trial, "Examining the efficacy of Non-invasive Neuromodulation in reducing symptoms of Multiple Sclerosis", is a double-blind, sham-controlled study of the safety and efficacy of Helius' Portable Neuromodulation Stimulator (PoNS(TM)) device, an investigational medical device that is designed to induce neuromodulation by stimulating the cranial nerves found in the tongue. A total of 14 subjects will receive treatment with the non-invasive brain stimulation device and concomitant physiotherapy designed to improve both balance and gait. The primary endpoint, at 14-weeks, is improvement in gait as quantified by the Dynamic Gait Index (DGI), Sensory Organization Test (SOT) and Functional Magnetic Resonance imaging (fMRI). The study is expected to conclude this summer.
Helius Medical Technologies Announces OTCQB Listing
Business Wire - Tue Feb 10, 11:44AM CST
Helius Medical Technologies, Inc. (CSE:HSM) (OTCQB:HSDT) ("Helius" or the "Company" is pleased to announce that its common shares have commenced trading on the OTCQB marketplace in the US, under the symbol HSDT.
U.S. Army, Helius Medical Technologies Modify CRADA To Speed PoNS(TM) Device Development
Business Wire - Mon Jan 19, 9:15AM CST
Helius Medical Technologies ("Helius", or the "Company" [through its wholly owned division NeuroHabilitation Corporation ("NHC"], and the U.S. Army Medical Research and Material Command ("USAMRMC" have modified an existing Cooperative Research and Development Agreement ("CRADA" to speed up the development of the company's Portable Neuromodulation Stimulator ("PoNS(TM)" device, a non-invasive brain stimulation device that is being developed for the treatment of balance disorder in patients with mild-to-moderate Traumatic Brain Injury ("mTBI". The PoNS(TM) is an investigational medical device that is designed to induce neuromodulation by stimulating the cranial nerves found in the tongue.
Helius Medical Technologies Inventors' Granted US Patent No. 8,909,345, "Non-Invasive Neuromodulation (NINM) for Rehabilitation of Brain Function"
Business Wire - Tue Dec 16, 9:15AM CST
Helius Medical Technologies, Inc. (CSE:HSM) ("Helius", or the "Company" announced today that the US Patent and Trademark Office (USPTO) issued a second broad patent related to the Portable Neuromodulation Stimulator (PoNS(TM)) device and the associated therapeutic modality. The PoNS, an investigational medical device that induces neuromodulation by stimulating the cranial nerves found in the tongue, is initially being studied for the treatment of balance disorder symptoms caused by Traumatic Brain Injury ("TBI" and MS.
Helius Medical Technologies Grants Stock Options and Adds to Scientific and Medical Advisory Board
Business Wire - Mon Dec 08, 7:48PM CST
Helius Medical Technologies (CSE:HSM) ("HMT", "Helius" or the "Company", a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, announces that it has granted incentive stock options, exercisable to purchase up to an aggregate of 950,000 shares of the Company, to directors, officers, and consultants of the Company.
Helius Medical Technologies Names Dr. Jonathan Sackier, MB ChB, FRCS, FACS, as Chief Medical Officer
TheNewswire.ca - Tue Dec 02, 10:35AM CST
(via Thenewswire.ca)
Helius Medical Technologies Grants Stock Options
ACCESSWIRE - Mon Mar 16, 4:49PM CDT
NEWTOWN, PA / ACCESSWIRE / March 16, 2015 / Helius Medical Technologies, Inc. (CSE: HSM; OTCQB: HSDT) ( "Helius" or "the Company"
, a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, announces that it has granted incentive stock options, exercisable to purchase up to an aggregate of 100,000 shares of the Company, to a director of Helius. Helius Medical Technologies Announces First Three Subjects Enrolled in Canadian Multiple Sclerosis Feasibility Study
Business Wire - Thu Feb 19, 9:15AM CST
Helius Medical Technologies ("Helius", or the "Company"
announced the enrollment of the first three subjects in the Multiple Sclerosis ("MS" feasibility study at the Montreal Neurological Institute and Hospital and Concordia's PERFORM Center. The trial, "Examining the efficacy of Non-invasive Neuromodulation in reducing symptoms of Multiple Sclerosis", is a double-blind, sham-controlled study of the safety and efficacy of Helius' Portable Neuromodulation Stimulator (PoNS(TM)) device, an investigational medical device that is designed to induce neuromodulation by stimulating the cranial nerves found in the tongue. A total of 14 subjects will receive treatment with the non-invasive brain stimulation device and concomitant physiotherapy designed to improve both balance and gait. The primary endpoint, at 14-weeks, is improvement in gait as quantified by the Dynamic Gait Index (DGI), Sensory Organization Test (SOT) and Functional Magnetic Resonance imaging (fMRI). The study is expected to conclude this summer. Helius Medical Technologies Announces OTCQB Listing
Business Wire - Tue Feb 10, 11:44AM CST
Helius Medical Technologies, Inc. (CSE:HSM) (OTCQB:HSDT) ("Helius" or the "Company"
is pleased to announce that its common shares have commenced trading on the OTCQB marketplace in the US, under the symbol HSDT. U.S. Army, Helius Medical Technologies Modify CRADA To Speed PoNS(TM) Device Development
Business Wire - Mon Jan 19, 9:15AM CST
Helius Medical Technologies ("Helius", or the "Company"
[through its wholly owned division NeuroHabilitation Corporation ("NHC"], and the U.S. Army Medical Research and Material Command ("USAMRMC" have modified an existing Cooperative Research and Development Agreement ("CRADA" to speed up the development of the company's Portable Neuromodulation Stimulator ("PoNS(TM)" device, a non-invasive brain stimulation device that is being developed for the treatment of balance disorder in patients with mild-to-moderate Traumatic Brain Injury ("mTBI". The PoNS(TM) is an investigational medical device that is designed to induce neuromodulation by stimulating the cranial nerves found in the tongue. Helius Medical Technologies Inventors' Granted US Patent No. 8,909,345, "Non-Invasive Neuromodulation (NINM) for Rehabilitation of Brain Function"
Business Wire - Tue Dec 16, 9:15AM CST
Helius Medical Technologies, Inc. (CSE:HSM) ("Helius", or the "Company"
announced today that the US Patent and Trademark Office (USPTO) issued a second broad patent related to the Portable Neuromodulation Stimulator (PoNS(TM)) device and the associated therapeutic modality. The PoNS, an investigational medical device that induces neuromodulation by stimulating the cranial nerves found in the tongue, is initially being studied for the treatment of balance disorder symptoms caused by Traumatic Brain Injury ("TBI" and MS. Helius Medical Technologies Grants Stock Options and Adds to Scientific and Medical Advisory Board
Business Wire - Mon Dec 08, 7:48PM CST
Helius Medical Technologies (CSE:HSM) ("HMT", "Helius" or the "Company"
, a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, announces that it has granted incentive stock options, exercisable to purchase up to an aggregate of 950,000 shares of the Company, to directors, officers, and consultants of the Company. Helius Medical Technologies Names Dr. Jonathan Sackier, MB ChB, FRCS, FACS, as Chief Medical Officer
TheNewswire.ca - Tue Dec 02, 10:35AM CST
(via Thenewswire.ca)
